{
    "clinical_study": {
        "@rank": "65603", 
        "arm_group": [
            {
                "arm_group_label": "Case", 
                "description": "Subject's with Crohn's disease at least 18 years of age"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Findings from this study will be compared to \"controls.\"  These controls will come from the well documented CNS changes which have been found in patients with IBS and chronic pancreatitis (HS-IRB# 2013-1561 and HS-IRB 2009-0171)."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary aims for this research are to 1) characterize brain changes in patients with CD\n      compared to age and gender-matched controls and 2) relate these brain changes to measures of\n      disease activity and pain severity."
        }, 
        "brief_title": "Brain-Gut Interactions in Crohn's Disease", 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years of age or older\n\n          -  A diagnosis of Crohn's disease by endoscopy or radiographic imaging\n\n          -  Must have Crohn's disease in symptomatic remission as defined by a Harvey-Bradshaw\n             score of 3\n\n          -  No contraindications to MRI per UWHC screening form\n\n          -  Able to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Women that are pregnant\n\n          -  Contraindications to MRI per UWHC screening form\n\n          -  Other chronic pain disorders (e.g. fibromyalgia, rheumatoid arthritis, irritable\n             bowel disorder) unrelated to their diagnosis of IBD.\n\n          -  Scheduled medications for the treatment of pain (e.g. acetaminophen, non-steroidal\n             anti-inflammatory drugs, narcotics) will be excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients 18 years of age or older diagnosed with CD, as determined by endoscopy or\n        radiographic imaging, will be targeted for enrollment.   Patients with CD in symptomatic\n        remission as defined by a Harvey-Bradshaw score of 3, will be eligible."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108938", 
            "org_study_id": "fMRI"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "contact": {
                "email": "kr2@medicine.wisc.edu", 
                "last_name": "Kelly J Richie, BS", 
                "phone": "608-262-5404"
            }, 
            "contact_backup": {
                "email": "jcsurfus@medicine.wisc.edu", 
                "last_name": "Jill C Surfus, BS", 
                "phone": "608-263-4185"
            }, 
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53792"
                }, 
                "name": "University of Wisconsin Hospital & Clinics"
            }, 
            "investigator": {
                "last_name": "Sumona Saha, MD, MS", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "CHARACTERIZING BRAIN-GUT INTERACTION IN PATIENTS WITH CROHN'S DISEASE USING ADVANCED NEUROIMAGING TOOLS", 
        "overall_contact": {
            "email": "kr2@medicine.wisc.edu", 
            "last_name": "Kelly J Richie, BS", 
            "phone": "608-262-5404"
        }, 
        "overall_contact_backup": {
            "email": "jcsurfus@medicine.wisc.edu", 
            "last_name": "Jill C Surfus, BS", 
            "phone": "608-263-4185"
        }, 
        "overall_official": {
            "affiliation": "University of Wisconsin, Madison", 
            "last_name": "Sumona Saha, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Because of the relatively large number of predictor variables in relation to the potential number of subjects, these analyses will be considered exploratory and aimed at generating hypotheses. Future studies with a larger number of subjects can be focused on hypothesis-driven questions and in developing diagnostic brain-based biomarkers and determining whether novel treatments aimed at the brain-gut axis may alter disease activity and pain perception in this patient population.", 
            "measure": "1) characterize brain changes in patients with CD compared to age and gender-matched controls", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108938"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Because of the relatively large number of predictor variables in relation to the potential number of subjects, these analyses will be considered exploratory and aimed at generating hypotheses. Future studies with a larger number of subjects can be focused on hypothesis-driven questions and in developing diagnostic brain-based biomarkers and determining whether novel treatments aimed at the brain-gut axis may alter disease activity and pain perception in this patient population.", 
            "measure": "2) relate these brain changes to measures of disease activity and pain severity.", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "University of Wisconsin, Madison", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Wisconsin, Madison", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}